PLA2G15: A Potential Drug Target Or Biomarker (G23659)

Target Name: PLA2G15

NCBI ID: G23659

PLA2G15

PLA2G15: A Potential Drug Target Or Biomarker

PLA2G15 (1-O-acylceramide synthase) is a protein that is expressed in various tissues throughout the body, including the liver, muscle, and brain. It is a key enzyme in the synthesis of 1-acylceramides, which are a type of lipid molecule that plays a crucial role in cellular signaling and energy metabolism.

Recent studies have identified PLA2G15 as a potential drug target or biomarker for various diseases, including cardiovascular disease, neurodegenerative diseases, and obesity. In this article, we will explore the biology and functions of PLA2G15 in more detail, as well as its potential as a drug target or biomarker.

PLA2G15 is a member of the superfamily of 1-acyl-CoA synthases, which are a group of enzymes that catalyze the synthesis of long-chain fatty acids from the monoacylglycerols (MAGs) found in cell membranes. These enzymes are critical for the maintenance of cellular energy homeostasis and are involved in a wide range of physiological processes, including cellular signaling, energy metabolism, and inflammation.

PLA2G15 is a key enzyme in the synthesis of 1-acylceramides, which are derived from MAGs and contain aacyl groups on their carbon chains. These molecules play a crucial role in cellular signaling, as they can interact with various signaling pathways and influence cellular behavior. For example, 1-acylceramides have been shown to play a role in the regulation of ion channels, cell adhesion, and neurotransmitter release.

In addition to its role in cellular signaling, PLA2G15 is also involved in energy metabolism and is a key enzyme in the synthesis of fatty acids from MAGs. These fatty acids are an essential component of cell membranes and are involved in a wide range of cellular processes, including energy storage and transport.

PLA2G15 is also involved in the regulation of inflammation and has been shown to play a role in the development of various inflammatory diseases, including cardiovascular disease and neurodegenerative diseases. For example, studies have shown that PLA2G15 is involved in the regulation of inflammation-related signaling pathways and that its expression is influenced by factors such as inflammation, obesity, and aging.

As a drug target or biomarker, PLA2G15 has the potential to be used for the treatment of a wide range of diseases. For example, recent studies have shown that inhibiting PLA2G15 can be effective in treating obesity and that this effect is mediated by the regulation of cellular signaling pathways, including the Obesity-related Hypothalamic-Pancreatic (ORH-P) axis. In addition, PLA2G15 has also been shown to be involved in the regulation of neurotransmitter release and may be a potential target for the treatment of neurodegenerative diseases.

In conclusion, PLA2G15 is a protein that is involved in a wide range of cellular processes and has been identified as a potential drug target or biomarker for various diseases. Its role in the synthesis of 1-acylceramides and its involvement in energy metabolism, signaling, and inflammation make it an attractive target for future research and clinical development. Further studies are needed to fully understand the biology and functions of PLA2G15 and its potential as a drug target or biomarker.

Protein Name: Phospholipase A2 Group XV

Functions: Has dual calcium-independent phospholipase and O-acyltransferase activities with a potential role in glycerophospholipid homeostasis and remodeling of acyl groups of lipophilic alcohols present in acidic cellular compartments (PubMed:10092508, PubMed:11790796, PubMed:20410020, PubMed:23958596, PubMed:29724779, PubMed:25727495). Catalyzes hydrolysis of the ester bond of the fatty acyl group attached at sn-1 or sn-2 position of phospholipids (phospholipase A1 or A2 activity) and transfer it to the hydroxyl group at the first carbon of lipophilic alcohols (O-acyltransferase activity) (PubMed:10092508, PubMed:11790796, PubMed:20410020, PubMed:23958596, PubMed:29724779, PubMed:25727495). Among preferred fatty acyl donors are phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols and phosphatidylserines (PubMed:29724779). Favors sn-2 over sn-1 deacylation of unsaturated fatty acyl groups of phosphatidylcholines and phosphatidylethanolamines (By similarity). Among preferred fatty acyl acceptors are natural lipophilic alcohols including short-chain ceramide N-acetyl-sphingosine (C2 ceramide), alkylacylglycerols, monoacylglycerols, and acylethanolamides such as anandamide and oleoylethanolamide (PubMed:29724779). Selectively hydrolyzes the sn-1 fatty acyl group of truncated oxidized phospholipids and may play a role in detoxification of reactive oxidized phospholipids during oxidative stress (PubMed:30830753). Required for normal phospholipid degradation in alveolar macrophages with potential implications in pulmonary surfactant clearance (By similarity). At neutral pH, hydrolyzes the sn-1 fatty acyl group of the lysophosphatidylcholines (PubMed:10092508)

The "PLA2G15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets